CYTOKINETICS INC

From the filings

Quoted directly from source documents.

• Cytokinetics is a late-stage biopharmaceutical company focused on muscle-directed medicines.

  “We are a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.”

  SEC MD&A · May 6, 2025

• Cash position as of March 31, 2026 was $1.1 billion.

  “Cash, cash equivalents, and investments was $ 1.1 billion as of March 31, 2026.”

  SEC MD&A · May 5, 2026

• Accumulated deficit was approximately $3.5 billion.

  “We have incurred an accumulated deficit of approximately $3.5 billion since inception and there can be no assurance that we will attain profitability.”

  SEC MD&A · February 26, 2026

• MYQORZO commercial sales began in Q1 2026.

  “We commenced commercial sales in the first quarter of 2026, but there can be no assurance as to the timing or level of revenues from such sales.”

  SEC MD&A · August 6, 2026

Catalyst timeline

• 2026-10-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Afica — Topline results from a pivotal Phase 3 trial of aficamten; outcome will significantly impact the drug's regulatory and commercial prospects.
• 2027-12-01 · Phase3_Topline — Phase 3 Topline: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of — Another Phase 3 topline readout for aficamten in a different indication, expanding potential label.
• 2028-03-01 · Phase3_Topline · aficamten — Phase 3 Topline: A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in H — Open-label extension data providing long-term safety and efficacy information for aficamten.
• 2028-09-29 · Phase3_Topline — Phase 3 Topline: A Phase 3, Randomized, Open-label, Multicenter Trial to Evaluate the Efficacy, Safety, and Tolerabil — Additional Phase 3 topline data for aficamten, further characterizing the drug's profile.
• 2030-01-01 · Phase3_Topline — Phase 3 Topline: A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial — Long-term Phase 2/3 data for aficamten, including placebo-controlled and open-label extension phases.